HBK INVESTMENTS L P - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 133 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2017. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.

Quarter-by-quarter ownership
HBK INVESTMENTS L P ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q4 2018$610,000
+138.3%
53,534
+353.7%
0.01%
+200.0%
Q3 2018$256,000
-76.5%
11,799
-80.9%
0.00%
-71.4%
Q2 2018$1,090,000
-77.0%
61,700
-79.4%
0.01%
-76.7%
Q3 2017$4,734,000
+396.7%
300,000
+1160.8%
0.03%
+200.0%
Q3 2015$953,00023,7940.01%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q4 2017
NameSharesValueWeighting ↓
Sarissa Capital Management LP 640,000$25,626,0006.33%
Redmile Group, LLC 1,322,592$52,957,0004.01%
SENZAR ASSET MANAGEMENT, LLC 556,224$22,271,209,0003.24%
RA Capital Management 314,349$12,587,0001.81%
WALL STREET ASSOCIATES 205,657$8,235,0001.58%
Parametrica Management Ltd 5,400$216,0001.36%
Rhenman & Partners Asset Management AB 165,000$6,607,0001.05%
EAM Investors, LLC 95,168$3,811,0000.60%
Rock Springs Capital Management LP 180,000$7,207,0000.58%
WASATCH ADVISORS LP 1,085,973$43,482,0000.58%
View complete list of INTRA CELLULAR THERAPIES INC shareholders